The collaboration will aim to identify Optimers for use as Optimer-drug conjugates for targeted delivery of diverse payloads to new cellular targets. Achieving targeted delivery of drugs to specific tissues and organs can increase the therapeutic dose at site of action to increase therapeutic efficacy, and reduce off-target effects to improve patient tolerability. This remains a major translational challenge for many new precision medicines.
As part of the agreement, Aptamer Group will develop Optimers to specific disease biomarkers and supply them to WuXi AppTec Research Service Division for further evaluation as potential delivery vehicles.
For the full story, please visit the Aptamer Group website.